Yufan Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yufan Zheng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Ontaneda
Mellen Center for Multiple Sclerosis, Cleveland Clinic, OH
2 shared publications - Kedar R. Mahajan
Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Neurosciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA
2 shared publications - Kunio Nakamura
Cleveland Clinic
2 shared publications - Robert J. Fox
Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
2 shared publications Bruce D Trapp
Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
1 shared publicationDanielle Herman
Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
1 shared publication
Latest Publications
- 3 August 2023
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 29 (10) , 1257-1265
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis
Background: Thalamic volume (TV) is a sensitive biomarker of disease burden of injury in multiple sclerosis (MS) and appears to reflect overall lesion loads. Ibudilast showed significant treatment effect on brain atrophy and magnetization transfer ratio (MTR) of normal-appearing brain tissue but not in new/enlarging T2 lesion in the SPRINT-MS randomized clinical trial. Objective: To evaluate the effect of ibudilast on thalamic tissue integrity and volume in the SPRINT-MS. Methods: A total of 255 participants with progressive MS were randomized to oral ibudilast or placebo, and thalamic MTR and normalized TV over 96 weeks were quantified. Mixed-effect modeling assessed treatment effects on the thalamic MTR and TV, separately. Similarly, the measures were compared between the participants with confirmed disability progression (CDP). Results: Ibudilast’s treatment effect was observed compared to placebo for thalamic MTR ( p = 0.03) but not for TV ( p = 0.68) while TV correlated with T2 lesion volume ( p < 0.001). CDP associated with thalamic MTR ( p = 0.04) but not with TV ( p = 0.7). Conclusion: Ibudilast showed an effect on thalamic MTR, which was associated with CDP, suggesting a clinically relevant effect on thalamic tissue integrity. However, the treatment effect was not observed in TV, suggesting that thalamic atrophy is more closely associated with global inflammatory activity than local tissue integrity. ClinicalTrials.gov: NCT01982942
- 3 August 2023
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 29 (10) , 1257-1265
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis
Background: Thalamic volume (TV) is a sensitive biomarker of disease burden of injury in multiple sclerosis (MS) and appears to reflect overall lesion loads. Ibudilast showed significant treatment effect on brain atrophy and magnetization transfer ratio (MTR) of normal-appearing brain tissue but not in new/enlarging T2 lesion in the SPRINT-MS randomized clinical trial. Objective: To evaluate the effect of ibudilast on thalamic tissue integrity and volume in the SPRINT-MS. Methods: A total of 255 participants with progressive MS were randomized to oral ibudilast or placebo, and thalamic MTR and normalized TV over 96 weeks were quantified. Mixed-effect modeling assessed treatment effects on the thalamic MTR and TV, separately. Similarly, the measures were compared between the participants with confirmed disability progression (CDP). Results: Ibudilast’s treatment effect was observed compared to placebo for thalamic MTR ( p = 0.03) but not for TV ( p = 0.68) while TV correlated with T2 lesion volume ( p < 0.001). CDP associated with thalamic MTR ( p = 0.04) but not with TV ( p = 0.7). Conclusion: Ibudilast showed an effect on thalamic MTR, which was associated with CDP, suggesting a clinically relevant effect on thalamic tissue integrity. However, the treatment effect was not observed in TV, suggesting that thalamic atrophy is more closely associated with global inflammatory activity than local tissue integrity. ClinicalTrials.gov: NCT01982942
- 20 May 2021
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 28 (2) , 198-205
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI
Detecting cortical demyelination using magnetic resonance imaging (MRI) in multiple sclerosis (MS) remains a challenge. Magnetization transfer ratio (MTR), T1-weighted/T2-weighted ratio (T1T2R), and T2-weighted (T2w) signal are sensitive to cortical demyelination, but their accuracy is unknown. To quantify the sensitivity, specificity, and accuracy of postmortem T1T2R, MTR, and T2w in detecting cortical demyelination. In situ postmortem MRIs from 9 patients were used to measure T1T2R, MTR, and T2w along the midline of cortical gray matter and classified as normal or abnormal. MRIs were co-registered and compared to hemispheric myelin staining. The sensitivity, specificity, and accuracy of T1T2R, MTR, and T2w in detecting cortical demyelination were measured. The mean age (standard deviation) at death was 64.7 (+/-13.7) years with a disease duration of 23.8 (+/-10.5) years. The sensitivity was 78% for MTR, 75% for T1T2R, and 63% for T2w. The specificity was 46% (T2w), 13% (T1T2R), and 29% (MTR). The accuracy was 71% (T2w), 39% (MTR), and 42% (T1T2R). There were no significant differences between different MRI measures in cortical demyelination or intracortical/subpial lesion detection. Although somewhat sensitive, the modest specificity of conventional MRI modalities for cortical demyelination indicates that they are influenced by cortical changes other than demyelination. Improved acquisition and post-processing are needed to reliably measure cortical lesion load.
- 20 May 2021
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 28 (2) , 198-205
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI
Detecting cortical demyelination using magnetic resonance imaging (MRI) in multiple sclerosis (MS) remains a challenge. Magnetization transfer ratio (MTR), T1-weighted/T2-weighted ratio (T1T2R), and T2-weighted (T2w) signal are sensitive to cortical demyelination, but their accuracy is unknown. To quantify the sensitivity, specificity, and accuracy of postmortem T1T2R, MTR, and T2w in detecting cortical demyelination. In situ postmortem MRIs from 9 patients were used to measure T1T2R, MTR, and T2w along the midline of cortical gray matter and classified as normal or abnormal. MRIs were co-registered and compared to hemispheric myelin staining. The sensitivity, specificity, and accuracy of T1T2R, MTR, and T2w in detecting cortical demyelination were measured. The mean age (standard deviation) at death was 64.7 (+/-13.7) years with a disease duration of 23.8 (+/-10.5) years. The sensitivity was 78% for MTR, 75% for T1T2R, and 63% for T2w. The specificity was 46% (T2w), 13% (T1T2R), and 29% (MTR). The accuracy was 71% (T2w), 39% (MTR), and 42% (T1T2R). There were no significant differences between different MRI measures in cortical demyelination or intracortical/subpial lesion detection. Although somewhat sensitive, the modest specificity of conventional MRI modalities for cortical demyelination indicates that they are influenced by cortical changes other than demyelination. Improved acquisition and post-processing are needed to reliably measure cortical lesion load.
- 6 April 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (14_supplem)
Long-Term Evolution Of Magnetization Transfer Ratio In Multiple Sclerosis Lesions (P4.016)
- 6 April 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (14_supplem)
Long-Term Evolution Of Magnetization Transfer Ratio In Multiple Sclerosis Lesions (P4.016)